Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is:

• To explore the potential role of tacrolimus in the treatment of membranous nephropathy.

• To investigate the safety and tolerability of tacrolimus vs methylprednisolone plus cyclophosphamide.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Nanjing University School of Medicine
• Treatments: Tacrolimus

Criteria

Inclusion Criteria:

• Biopsy-proven idiopathic membranous nephropathy

• Nephrotic syndrome with proteinuria ( > 4 g/day) and serum albumin < 30 g/dl

• Age 18-60 years with informed consent

Exclusion Criteria:

• Patient with abnormal liver function tests

• Prior therapy with sirolimus, CSA, MMF, or azathioprin, cytoxan, chlorambucil, levamisole, methotrexate, or nitrogen mustard in the last 90 days

• Active/serious infection

• Patient with hepatitis B surface antigen or who is hepatitis C antibody positive

• Patient who is diabetic

• Patient is allergic or intolerant to macrolide antibiotics or tacrolimus